Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse

Једноставна страница ставке
dc.citation.epage15
dc.citation.spage10
dc.citation.volume26
dc.contributor.authorDukić, Nikolina
dc.contributor.authorGojković, Zdenka
dc.contributor.authorVladičić-Mašić, Jelena
dc.contributor.authorMašić, Srđan
dc.contributor.authorLalović, Nenad
dc.contributor.authorPopović, Slađana
dc.date.accessioned2023-07-10T10:37:23Z
dc.date.available2023-07-10T10:37:23Z
dc.date.issued2020
dc.description.abstractOf all breast cancers 20-25% are HER2 positive. Overexpression of HER2 protein on the surface of the malignant cell leads to excessive cell proliferation through different signaling pathways. Trastuzumab is a human monoclonal antibody that binds to domain IV of HER2 receptor and blocks signaling pathway for proliferation. The result is an improved prognosis for HER 2 positive breast cancer patients, even when compared to patients with other types of breast cancers. Methods: The study presents 74 women patients with early HER2 positive breast cancer who were previously operated (either radicaly or using breast conserving surgery), and received adjuvant chemo- and radiotherapy. Fourty four patients received adjuvant trastuzumab for one year, and 30 patients did not (control group). Observed time to relapse of the disease was 60 months. Results: There was a significant difference in survival in favor of the group that received trastuzumab (p<0.001). Application of trastuzumab also delayed relapse of the disease by 51.7%. No significant difference was observed between estrogen receptor positive and estrogen receptor negative cancers., In the control group there was a significant difference in relapse free survival in favor of estrogen and progesteron receptor positive tumors (p<0.001). Conclusion: Survival of patients with a HER2 positive breast cancer whose prognosis was initially worse compared to HER2 negative patients, significantly improved after administration of trastuzumab.
dc.identifier.doi10.2298/AOO181112006D
dc.identifier.urihttps://vaseljena.ues.rs.ba/handle/123456789/395
dc.language.isoen
dc.publisherOncology Institute of Vojvodina, Serbia
dc.sourceArchive of Oncology
dc.subjectCancer, Breast, Tyrosine kinase receptor, HER2, Trastuzumab, Prognosis, Antibodies
dc.titleAdjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
dc.typeArticle
Датотеке
Оригинални завежљај
Сада се приказује 1 - 1 од 1
Сличица
Име:
Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse.pdf
Величина:
425.74 KB
Формат:
Adobe Portable Document Format
Опис:
Преузимање
Свежањ лиценце
Сада се приказује 1 - 1 од 1
Сличица
Име:
license.txt
Величина:
1.71 KB
Формат:
Item-specific license agreed to upon submission
Опис:
Преузимање
Колекције
Медицински факултет [Научни радови] / Faculty of Medicine [Scientific papers]